NEWLY-ENGINEERED SYNTHETIC AFGP STABLE/NON-TOXIC.

The University of Rouen in France has reported that their laboratory has completed an enzymatic study on the dimeric compound of synthetic AFGP, which resulted in zero degradation. This confirmation of the stability of the dimeric class of AFGP illustrates that the newly engineered molecule has maintained the same stable characteristic as the monomeric predecessor.

Dr. Geraldine Deliencourt reported, from the laboratory at Rouen, that she has just received results from a cytotoxic (safety) study on the very sensitive vero (kidney) cells with the dimeric AFGP. The results showed the dimeric AFGP to be non-toxic in the same manner the monomeric AFGP tested. These confirmations of stability and non-toxicity are critically important for the successful commercialization of synthetic AFGP.

These findings allow ProtoKinetix (OTCBB:PKTX) to immediately commence testing this new compound (dimeric AFGP) on cell lines and tissues in France and Canada. Management anticipates that this advanced engineered molecule will exhibit superior results to the already successful monomeric synthetic AFGP. This second generation AFGP is a clear indication of the company's ability to customize this molecule with desired characteristics to adapt to the cell line or tissue being preserved.

About ProtoKinetix:

ProtoKinetix, Inc. is a scientific development company whose mission is the advancement of human health care. The company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.

For more information, call 888/772-1288 or 760/230-2300, ext. 206.